glp-1 and ulcerative colitis medications are a major focus for scientists right now., Here’s what’s happening: between 2024 and 2025, at least six studies have been published in respected journals Protective effect of Dulaglutide, a

Description

Data extraction and synthesis A detailed data extraction table was developed on Microsoft Excel and data on key study characteristics and outcomes were collected

Results from a study examining the safety of using liraglutide in patients with moderate to severe renal impairment demonstrated no deleterious effects on serum creatinine (SCr) or increased incidence or severity of adverse events

In the future, with increasing demand for personalized treatment and continuous technological advancements, peptibody drugs are expected to show promising prospects in various aspects

Key end points included: hospitalisation, heart failure (ICD-10-CM-I50), myocardial infarction (ICD-10-CM-I21), stroke and transient ischaemic attack (ICD-10-CM-I63, G45), development of diabetic microvascular complications (ICD-10-CM-E10.210.4) and all-cause mortality analysed 3 months to 5 years post drug initiation